See more : American Express Company (AXP) Income Statement Analysis – Financial Results
Complete financial analysis of DIAGNOS Inc. (DGNOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DIAGNOS Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- JPMorgan Global Core Real Assets Limited (JARE.L) Income Statement Analysis – Financial Results
- PT XL Axiata Tbk (EXCL.JK) Income Statement Analysis – Financial Results
- Paik Kwang Industrial Co., Ltd. (001340.KS) Income Statement Analysis – Financial Results
- Dufry AG (0QK3.L) Income Statement Analysis – Financial Results
- co.don AG (CNWK.DE) Income Statement Analysis – Financial Results
DIAGNOS Inc. (DGNOF)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.diagnos.ca
About DIAGNOS Inc.
DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. The company was founded in 1998 and is headquartered in Brossard, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 170.16K | 438.83K | 267.07K | 331.52K | 326.47K | 326.47K | 1.61M | 2.39M | 981.48K | 564.18K | 2.70M | 1.51M | 1.33M | 1.07M | 358.07K | 1.89M | 1.86M | 775.72K | 709.19K | 111.75K | 387.72K | 128.62K | 7.00K |
| Cost of Revenue | 1.01M | 857.13K | 614.60K | 804.97K | 1.09M | 1.09M | 1.32M | 1.67M | 1.18M | 1.11M | 2.24M | 1.02M | 104.54K | 24.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -837.94K | -418.30K | -347.53K | -473.46K | -759.37K | -759.37K | 290.90K | 719.10K | -203.51K | -541.43K | 464.53K | 490.00K | 1.22M | 1.05M | 358.07K | 1.89M | 1.86M | 775.72K | 709.19K | 111.75K | 387.72K | 128.62K | 7.00K |
| Gross Profit Ratio | -492.45% | -95.32% | -130.13% | -142.81% | -232.60% | -232.60% | 18.04% | 30.09% | -20.73% | -95.97% | 17.17% | 32.47% | 92.13% | 97.68% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 1.08M | 603.35K | 0.00 | 0.00 | 0.00 | 922.49K | 0.00 | 1.18M | 1.07M | 1.31M | 1.00M | 831.56K | 793.96K | 614.13K | 618.21K | 674.24K | 193.82K | 101.25K | 179.58K | 784.10K | -4.56K | 192.92K | 1.44M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.84M | 2.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -293.72K | -295.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.77M | 2.24M | 1.94M | 2.32M | 2.17M | 2.17M | 2.76M | 2.69M | 2.52M | 2.13M | 2.11M | 2.55M | 2.46M | 2.10M | 1.69M | 3.23M | 2.02M | 1.39M | 1.09M | 1.10M | 426.23K | 567.04K | 1.45M |
| Other Expenses | 0.00 | 100.14K | 264.28K | 85.80K | 52.31K | 52.31K | 0.00 | 0.00 | 1.07M | 0.00 | 0.00 | -374.80K | -240.63K | -204.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.76M | 2.24M | 1.94M | 2.32M | 2.17M | 2.17M | 2.76M | 2.69M | 2.52M | 2.13M | 2.11M | 2.55M | 3.15M | 2.66M | 2.28M | 4.04M | 2.29M | 1.52M | 1.30M | 1.91M | 496.73K | 899.32K | 3.06M |
| Cost & Expenses | 3.86M | 3.10M | 2.55M | 3.13M | 3.26M | 3.26M | 4.08M | 4.36M | 3.70M | 3.23M | 4.35M | 3.56M | 3.25M | 2.69M | 2.28M | 4.04M | 2.29M | 1.52M | 1.30M | 1.91M | 496.73K | 899.32K | 3.06M |
| Interest Income | 6.89K | 5.38K | 5.38K | 3.23K | 3.23K | 1.48K | 0.00 | 0.00 | 0.00 | 0.00 | 5.23K | 11.89K | 27.01K | 8.79K | 15.44K | 76.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 550.17K | 53.78K | 32.16K | 347.11K | 1.03M | 1.03M | 827.77K | 955.38K | 469.22K | 159.40K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.25K | 0.00 | 0.00 |
| Depreciation & Amortization | 124.21K | 101.17K | 105.80K | 92.84K | 101.72K | 191.32K | 230.19K | 192.65K | 82.37K | 43.71K | 62.19K | 89.52K | 81.36K | 125.94K | 186.17K | 188.36K | 79.67K | 32.68K | 29.28K | 23.66K | 75.05K | 139.36K | 176.19K |
| EBITDA | -2.45M | -2.10M | -2.45M | -2.61M | -2.69M | -2.69M | -2.66M | -1.78M | -2.64M | -2.62M | -1.58M | -1.97M | -1.84M | -1.49M | -1.74M | -1.97M | -347.40K | -711.98K | -560.21K | -1.77M | -33.96K | -631.34K | -2.88M |
| EBITDA Ratio | -1,437.61% | -557.99% | -723.29% | -785.96% | -822.85% | -822.39% | -164.64% | -74.54% | -269.07% | -465.19% | -58.55% | -130.30% | -134.65% | -184.81% | -485.96% | -104.35% | -18.65% | -91.78% | -78.99% | -1,587.96% | -8.76% | -490.86% | -41,123.96% |
| Operating Income | -3.69M | -2.55M | -2.02M | -2.71M | -2.88M | -2.88M | -2.89M | -1.97M | -2.72M | -2.67M | -1.65M | -2.06M | -2.22M | -1.58M | -1.93M | -2.16M | -427.07K | -744.66K | -589.49K | -1.80M | -109.01K | -770.70K | -3.05M |
| Operating Income Ratio | -2,168.30% | -582.10% | -756.03% | -816.65% | -881.45% | -881.00% | -178.91% | -82.60% | -277.46% | -472.94% | -60.85% | -136.23% | -167.19% | -147.33% | -537.96% | -114.34% | -22.92% | -96.00% | -83.12% | -1,609.13% | -28.12% | -599.21% | -43,640.96% |
| Total Other Income/Expenses | 568.95K | -259.14K | 608.66K | 232.12K | -505.21K | -1.03M | -622.77K | 232.83K | 475.50K | -159.40K | 5.23K | 11.89K | 27.01K | 275.63K | 0.00 | 0.00 | 0.00 | 124.41K | 8.37K | 64.85K | 26.20K | -57.70K | -123.17K |
| Income Before Tax | -3.12M | -2.61M | -2.05M | -3.38M | -3.90M | -3.90M | -3.09M | -2.93M | -3.19M | -2.83M | -1.64M | -2.04M | -2.19M | -1.31M | 0.00 | 0.00 | 0.00 | -620.25K | -581.12K | -1.73M | -82.81K | -828.40K | -3.18M |
| Income Before Tax Ratio | -1,833.93% | -594.35% | -768.07% | -1,020.42% | -1,195.74% | -1,195.74% | -191.55% | -122.57% | -325.27% | -501.19% | -60.66% | -135.44% | -165.16% | -121.68% | 0.00% | 0.00% | 0.00% | -79.96% | -81.94% | -1,551.10% | -21.36% | -644.07% | -45,400.57% |
| Income Tax Expense | 0.00 | 153.92K | 296.44K | 432.91K | -64.67K | -64.67K | -192.19K | -1.32M | 0.00 | 0.00 | 0.00 | -540.22K | 28.02K | -508.81K | -15.44K | -76.43K | -28.99K | -3.12K | 747.00 | 12.79K | 47.25K | -33.48K | 4.58K |
| Net Income | -3.12M | -2.61M | -2.05M | -3.38M | -3.84M | -3.84M | -2.90M | -2.93M | -3.19M | -2.83M | -1.64M | -2.04M | -2.19M | -1.31M | -1.91M | -2.08M | -398.09K | -617.13K | -581.86K | -1.75M | -130.06K | -762.98K | -3.18M |
| Net Income Ratio | -1,833.93% | -594.35% | -768.07% | -1,020.42% | -1,175.93% | -1,175.93% | -179.63% | -122.57% | -325.27% | -501.19% | -60.66% | -135.44% | -165.16% | -121.68% | -533.64% | -110.28% | -21.37% | -79.56% | -82.05% | -1,562.55% | -33.54% | -593.21% | -45,465.96% |
| EPS | -0.04 | -0.04 | -0.03 | -0.05 | -0.09 | -0.20 | -0.17 | -0.24 | -0.30 | -0.29 | -0.21 | -0.31 | -0.35 | -0.25 | -0.40 | -0.46 | -0.10 | -0.17 | -0.18 | -0.65 | -0.09 | -0.71 | -1.06 |
| EPS Diluted | -0.04 | -0.04 | -0.03 | -0.05 | -0.09 | -0.20 | -0.17 | -0.24 | -0.30 | -0.29 | -0.21 | -0.31 | -0.35 | -0.25 | -0.40 | -0.46 | -0.10 | -0.17 | -0.18 | -0.65 | -0.09 | -0.71 | -1.06 |
| Weighted Avg Shares Out | 72.82M | 69.62M | 68.73M | 63.11M | 40.74M | 18.84M | 16.89M | 12.37M | 10.62M | 9.85M | 7.78M | 6.58M | 6.20M | 5.23M | 4.80M | 4.56M | 4.07M | 3.62M | 3.15M | 2.68M | 1.41M | 1.07M | 3.00M |
| Weighted Avg Shares Out (Dil) | 72.82M | 69.62M | 68.73M | 63.11M | 40.74M | 18.84M | 16.89M | 12.37M | 10.62M | 9.85M | 7.78M | 6.58M | 6.20M | 5.23M | 4.80M | 4.56M | 4.07M | 3.62M | 3.15M | 2.68M | 1.41M | 1.07M | 3.00M |
DIAGNOS Announces Exercise of Stock Warrants and Provides a Cash Update
BROSSARD, Quebec, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces...
DIAGNOS Announces its Exclusive Strategic Partnership Agreement with Labtician Ophthalmics, a Leader in Canadian and International Eyecare Markets to Address Growing Needs in the Monitoring of Diabetic and Hypertensive Patients
BROSSARD, Quebec, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI),...
DIAGNOS Announces Further Deployment of its AI based CARA Technology in Saudi Arabia
BROSSARD, Quebec, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI),...
DIAGNOS announces the re-opening of its medical testing in Panama
BROSSARD, Quebec, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI),...
DIAGNOS Successfully Completes ISO 13485 / MDSAP Audit
BROSSARD, Quebec, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence...
DIAGNOS announces a 3-year partnership agreement with the University of Montreal Hospital Centre (CHUM) on the use of Artificial Intelligence
BROSSARD, Quebec, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or "Company") (TSX Venture Exchange: ADK) (OTCQB: DGNOF), a leader in early detection of critical health problems through the use of artificial intelligence (AI), announces a three (3) year...
Source: https://incomestatements.info
Category: Stock Reports